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Background : Recently, studies have concerned on the use of xanthones for treating patients with cardiovascular 
diseases. In our country, xanthones were found in Garcinia Mangostana Linn.
Objectives : To assess the effect of Garcinia Mangostana Linn Extract (GMLE) to the levels of Circulating Endotheli-
al Cells (CEC) and Endothelial Progenitor Cells (EPC) in patients with high framingham score.
Methods : A prospective cohort study was conducted from November 2018 to January 2019. The patients were 
divided into two groups. The first group was given 2520 mg/day of GMLE for 90 days and the second group was 
given placebo. In sub group analyses, patients were divided based on previous medication, including statin, statin 
and angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB), statin and oral 
antidiabetic drugs (OAD), and statin and ACEI or ARB and OAD. The outcome measures were CEC and EPC 
levels, measured at baseline and after 90 days of treatment. We used multiple linear regression to analyze the 
correlation and effect estimates.
Results: A total of 72 patients was included in our study. All of the patients baseline characteristics were distribut-
ed homogeneously (p>0.05). Our findings confirmed that GMLE administration was associated with decreased 
CEC level compared to placebo. On other hands, increased EPC level compared to placebo was observed after 
GMLE administration. In sub-group analyses, our study found that the combination of GMLE with statin and ACEI 
or ARB and the combination of GMLE with statin and ACEI or ARB and OAD were associated with decreased level 
of CEC compared to placebo, with the odd ratios were 0.12 and 0.18, respectively. Conversely, increased level of 
EPC was observed in subjects receiving the combination of GMLE with statin and ACEI or ARB and the combina-
tion of GMLE with statin. 
Conclusion: Administration of GMLE as adjuvant therapy is associated with the improvement of CEC and EPC 
levels in patients with high framingham scores.
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 Cardiovascular diseases remain the leading cause of mortali-
ty worldwide. It was reported that the global mortality caused by 
cardiovascular disease was ranging from 59.9 to 120.4 per 100,000 
population. This number was estimated to increase about 3-fold in 
2030.1 In our country, the reports revealed that the mortality was about 
37%. However, the precise number was estimated higher due to limited 
reports while the risk factors of cardiovascular disease in
Indonesia are complicated. Moreover, the risk factors of cardiovascular 
disease in our country including dyslipidemia, hypertension, and 
diabetes mellitus were reported to have increased trend over periods.2 
Therefore, an approach to resolve this problem is required through 
both pre-clinical and clinical approach.
 Recently, studies have focused on the inflammation as the 
target of endothelial dysfunction therapy.3,4 The process of inflamma-
tion in endothelial dysfunction is complex, and involves several 
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factors.5 However, studies have concerned to assess the role of Circulat-
ing Endothelial Cells (CEC) and Endothelial Progenitor Cells (EPC) in 
endothelial dysfunction.6,7 Several studies had shown that CEC and EPC 
played an important role in the development of atherosclerosis.8,9 
Moreover, studies had found that therapies targeting CEC and EPC 
were associated with better outcome.10,11
 In our country, it has been widely known that a large amount 
of plants is existed. The used of active compound from plants had been 
shown to have benefits effects in some diseases, especially in cardiovas-
cular diseases.12 In the context of cardiovascular diseases, studies had 
shown several compounds to have anti-inflammatory effects including 
xanthones,13 Tribulus terrestris extrac, Aqueous extract of Ocimum 
basilicum, salvianolic acid B,  and Ethanol extract of Cynanchum 
wilfordii.14 However, recent studies showed that plants containing 
xanthones (α and γ mangosteen) were associated with better outcome 
in several cardiovascular diseases including ischemic heart disease, 
atherosclerosis, hypertension and thrombosis.13,15 Moreover, xanthones 
were also reported to provide decreased level of oxidant and the 
number of foam cells.16 Interestingly, studies also found that xanthones 
had no toxicity, suggesting that xanthones were safe for patients with 
cardiovascular diseases.17,18 In our country, xanthones are widely found 
in Garcinia Mangostana Linn. Therefore, Garcinia Mangostana Linn 
Extract (GMLE) might provide beneficial effects in patients with cardio-
vascular diseases, especially in patients with high framingham score. 
 Our present study, therefore, aimed to assess the correlation 
between the administration of GMLE and the levels of CEC and EPC in 
patients with high framingham score. Our present study might provide 
baseline data of the role of GMLE in patients with cardiovascular 
diseases. 
 
2. Methods
2.1. Study Design
 A prospective cohort study was conducted during November 
2018 to January 2019 in dr. Saiful Anwar Hospital, Malang, Indonesia. 
To assess the correlation between the administration of GMLE and the 
levels of CEC and EPC in patients with high framingham score, study 
participants were divided into two groups, GMLE and placebo, and data 
regarding the levels of CEC and EPC were collected at baseline and 90 
days after treatment. To assess the correlation and effect estimates, 
data were analyzed using multiple linear regression.
2.2. Ethical approval
 The study protocols were conducted in accordance with the 
Declaration of Helsinki and were approved by the Institutional Review 
Board, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia 
(No: 64/EC/KEPK/03/2018). The aims, risks, and benefits of the study 
were explained to each participant, and they were asked to sign a 
consent form prior to enrolment in the study. Participants were also 
informed that they could quit at any time during the study session. 
Participations in this study were voluntary and no incentive was given. 
2.3. Participants & eligibility criteria
 To represent the total population, 30 participants were 
required as the minimum sample size based on the assumption that the 
prevalence of cardiovascular disease patients with high framingham 
score was 30% with a 5% margin of error and 95% confidence level. 
Data of sample frame was obtained from medical record in our 
Hospital. The recruitment of participants was conducted using a simple 
random sampling procedure. Inclusion criteria were (1) diagnosed 
having cardiovascular disease with high framingham score on the basis 
of clinical, biochemical, and electrocardiographic criteria for more than 
three months, (2) clinically stable and recovered, (3) having ability to 
communicate in Bahasa Indonesia. Patients with the following 
conditions: elevated levels of serum glutamic oxaloacetic transaminase 
(SGOT) / serum glutamic pyruvic transaminase (SGPT), urea, 
creatinine, prolonged blood coagulation, on routine therapy of Nonste-
roidal anti-inflammatory drugs (NSAIDs), and patient with drug or 
narcotic abuse were excluded from the study. The study population was 
all high risk group patients according to the framingham cardiovascular 
risk score criteria. A total of 72 patients were divided into the treatment 
group (GMLE) and the control group with a combination of routine 
treatment that has been consumed previously. For GMLE group, three 
patients received GMLE, 13 patients received GMLE and Angioten-
sin-converting-enzyme inhibitors (ACEI) or angiotensin II receptor 
blockers (ARBs), three patients received GMLE and oral anti diabetic, 
and 14 patients received a combination of GMLE and ACEI or ARB and 
oral anti diabetic. The GMLE administration was conducted for 90 days.
2.4. Measure
 The baseline data, measured prior to GMLE administration, 
included age, gender, blood pressure, complete blood count, coagula-
tion factors, SGOT/SGPT, urea, creatinine, lipid profile, blood glucose, 
and lipid profile. The outcome measures in our present study were the 
levels of CEC and EPC, measured before and after GMLE administra-
tion. All laboratory tests in our present study were conducted in 
Pattimura Laboratorium. 
2.5. Statistical Analysis
 To determine the correlation and effect estimates between 
the administration of GMLE and the levels of CEC and EPC in patients 
with high framingham score, data were analyzed using multiple linear 
regression. The p value of less than 0.05 was considered statistically 
significant. Prior to determine the correlation, data were assessed for 
homogeneity by using paired t-test and chi-square. All statistical 
analyses in our present study were conducted using the Statistical 
Package for Social Sciences software (SPSS for Windows, version 16, 
Chicago, USA). 
3. Results
3.1. Patients Selections
 During March to May 2017, a total of 123 patients with high 
framingham score was identified. Of those, a total of 51 patients was 
excluded because of elevated levels of SGOT and SGPT (12), urea and 
creatinine (26), prolonged blood coagulation (7), and on routine 
therapy with NSAID (18). Finally, we included 72 patients in our study, 
divided into 33 patients given GMLE and 39 patients given placebo. A 
flowchart describing eligibility pathway in our study is provided in Fig 
1.
3.2. Baseline Characteristics
 Approximately one-third of the participants was men 
(58.9%) with mean age and body mass index were 63.35 years and 
25.79 kg/m2, respectively. Other baseline characteristics of patients 
included in our present study are summarized in Table 1. The baseline 
characteristics between patients receiving GMLE and placebo had p 
value of more than 0.05, suggesting that data were distributed homoge-
neously between groups.
3.2. Main Findings
 A total of 33 patients receiving GMLE and 39 patients receiv-
ing placebo was enrolled in our study. Our overall analysis found that
33
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Table 1. Baseline characteristics of patients included in our study before treatment
Figure 1. A flowchart of eligibility pathway in this study
Note, Data were presented in mean ± SD or n[%]; GMLE, Garcinia Mangostana Linn Extract; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; HbA1C, 
hemoglobin A1c; CEC, Circulating endothelial cells; EPC, Endothelial progenitor cells. 
Variables GMLE (n=33) Placebo (n=39) p 
Age 64.21±8.40 62.50 ± 10.30 0.6400 
Sex (Male) 10 (30.3%) 13 (33.3%) 0.8060 
Body mass index 25.18 ± 5.34 26.4 ± 4.06 0.3470 
Framingham score 29.6 ±17.38 35.09 ± 22.02 0.2890 
Sistolic blood pressure 155 ± 8.80 147 ± 15.30 0.0090 
Diastolic blood pressure 87 ±14.30 88.5 ± 10.90 0.4980 
Total cholesterol 227.00 ± 24.97 221.60 ± 34.71 0.4940 
Triglyseride 156.50 ± 88.07 152.90 ± 102.40 0.8600 
HDL 48.45 ± 13.12 45.56 ± 11.66 0.4980 
LDL 116.05 ± 34.26 115.4 ± 34.18 0.9010 
Fasting blood glucose 115.64 ± 42.39 138.49 ± 63.86 0.0940 
CEC 1.23 ± 72.89 1.07 ± 82.05 0.9140 
EPC 100.81 ± 46.79 99.34 ± 45.03 0.9270 
A total of 123 patients with high framingham score
A total of 51 patients were excluded
A total of 72 patients were included in our study
1. 12 patients were excluded because of elevated levels of SGOT and SGPT
2. 26 patients were excluded beacuse of elevated levels of urea and creatinine
3. 7 patients were excluded because of prolonged blood coagulation
4. 18 patients were excluded because of on routine therapy with NSAID
GMLE administration was associated with decreased level of CEC 
compared to placebo (OR95%CI = 0.17 [0.07 - 0.41], p<0.0001). 
Conversely, 15-fold elevated level of EPC was found in patients receiv-
ing GMLE compared to placebo (OR95%CI = 15.83 [6.10 - 41.09], 
p<0.0001). The summary of CEC and EPC levels between patients 
patients receiving GMLE and placebo is described in Table 2.
Parameters GMLE (n=33) Placebo (n=39) OR 95%CI p 
 CEC (cells/µL) -62.53 ± 70.63 -3.97 ± 49.11 0.17 0.07 - 0.41 <0.0001 
EPC (cells/µL) 16.77 ± 20.81 -22.90 ± 30.35 15.83 6.10 - 41.09 <0.0001
Note, data were presented in mean ± SD; GMLE, Garcinia Mangostana Linn Extract; OR, odds ratio; CI, confidence interval. 
Table 2. The comparison of ∆ CEC and ∆ EPC between groups
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 In sub-group analysis, for CEC level, our findings found that 
the combination of GMLE with statin and ACEI or ARB was associated 
with decreased level of EPC compared to placebo (OR05%CI = 0.12 
[0.05 - 0.29], p<0.0001). Subsequently, compared to placebo, 
decreased level of CEC was also observed in patients receiving the 
combination of GMLE with statin and ACEI or ARB and OAD (OR95%CI 
= 0.18 [0.07 - 0.43], p<0.0001). The summary of the comparison of 
CEC level between groups with drugs combination is provided in Table  
3. Furthermore, for EPC level, we revealed that increased level of EPC 
was found in patient receiving the combination of GMLE with statin and 
ACEI or ARB (OR95%CI = 22.04 [8.27 - 58.79], p<0.0001). We also 
found that elevated level of EPC was also observed significantly higher 
in patient recieving the combination of GMLE with statin and OAD 
(OR95%CI = 13.18 [5.14 - 33.74], p<0.0001). We summarized the 
comparison of EPC level between groups with drugs combination in 
Table 4. 
4. Discussion
 Our results found that the administration of GMLE as an 
adjuvant therapy in patients with high framingham score was associat-
ed with decreased level of CEC. During this time, no study reported the 
effect of GMLE as an adjuvant therapy in patients with high framing-
ham score. However, in other disease settings, studies had found that 
decreased level of CEC was observed in patients with hypertension,19 
diabetes mellitus,20 and dyslipidemia21 after administration of GMLE as 
and adjuvant therapy. The theory explaining this correlation was 
arduous to explain. However, some speculations regarding the role of 
CEC in the process of atherosclerosis have been proposed. A study 
revealed that the level of CEC in circulation was closely related to the 
severity of endothelial dysfunction,22 the higher CEC level the higher 
degree of endothelial dysfunction severity.23 Another study also 
supported the speculation. They showed that the positive correlation 
regarding the number of CEC and carotid plaque score was found,24 
suggesting that CEC might play a pivotal role as one of the biomarkers 
of endothelial dysfunction severity. Subsequently, previous studies had 
found that GMLE contained xanthones (α and γ mangosteen).25 The 
precise mechanism of GMLE in the pathogenesis of endothelial dysfunc-
tion had not been clearly elucidated. However, the evidence revealed 
that xanthones administration as an adjuvant therapy was associated 
with better outcome in several cardiovascular diseases including 
atherosclerosis,26 hypertension, and dyslipidemia.15 Moreover, xantho-
nes were also found to provide decreased level of oxidant and the 
number of foam cells.16 Therefore, implicitly, the lower level of CEC 
after administration of GMLE as an adjuvant therapy in patients with 
high framingham score was made sense. This explanation might 
describe the probable mechanism between GMLE administration as an 
adjuvant therapy and the level of CEC in patients with high framingham 
score.
 We found that increased level of EPC was observed in 
patients with high framingham score receiving GMLE compared to 
placebo. Until now, we found no study evaluating the role of GMLE to 
the level of EPC in patients with high framingham score. However, in 
the case of hypertension,27 diabetes mellitus,28 and dyslipidemia;15 
studies had found the correlation between the administration of GMLE 
and the level of EPC, indicating that GMLE is the important component 
involved in the development of endothelial dysfunction. Moreover, it 
was also revealed that EPC had a negative correlation with the progres-
sion of atherosclerosis by playing a role in regenerating damaged 
vascular endothelium.29 While it had been proposed that GMLE had an 
important role in the process of endothelial dysfunction, further studies 
are required to elucidate the precise mechanisma on how GMLE affect 
the level of EPC in patients with high framingham score.
 In sub - group analysis, we tried to identify in specific 
conditions the role of GMLE to the levels of CEC and EPC in patients 
with high framingham score, including in patients with diabetes 
mellitus, hypertension, and dyslipidemia. Overall, our results 
conformed with our main findings, showing that GMLE was associated 
with decreased level of CEC, and vise versa, GMLE was correlated with 
increased level of EPC in patients with high framingham score. Our 
findings were consistent with the previous study in the case of diabetes 
mellitus.28 They also found that GMLE administration was associated 
with increased and decreased levels of EPC and CEC, respectively, in 
35
Combination with GMLE Placebo OR 95%CI p 
Statin -39.50 ±19.24 -24.41 ± 93.09  0.66 0.28 - 1.53 0.3330 
Statin + ACEI / ARB -48.00 ± 63.89 12.24 ± 36.08  0.12 0.05 - 0.29 <0.0001 
Statin + OAD -18.00 ± 27.66 -34.79 ± 81.78  1.63 0.70 - 3.79 0.2580 
Statin +ACEI / ARB + OAD -90.44 ± 81.91 0.35 ± 20.49  0.18 0.07 - 0.43 <0.0001 
Combination with GMLE Placebo OR 95%CI p 
Statin 15.80 ± 35.63 -12.48  16.32 0.14 0.06 - 0.35 <0.0001  
Statin + ACEI / ARB 20.11 ± 17.46 -27.45 ± 34.19  22.04 8.27 - 58.79 <0.0001  
Statin + OAD 4.30 ± 11.75 -18.90 ± 18.95  13.18 5.14 - 33.74 <0.0001  
Statin +ACEI / ARB + OAD 26.56 ± 22.82 -24.12 ± 34.24  23.04 8.61 - 61.68 0.9270  
Table 3. Comparison of ∆ CEC between groups with drugs combination
Note, data were presented in mean ± SD; GMLE, Garcinia Mangostana Linn Extract; OR, odds ratio; CI, confidence interval; ACEI, Angiotensin-converting-enzyme 
inhibitors; ARB, Angiotensin II receptor blockers; OAD, Oral antidiabetic drugs.
Table 4. Comparison of ∆ EPC between groups with drugs combination
Note, data were presented in mean ± SD; GMLE, Garcinia Mangostana Linn Extract; OR, odds ratio; CI, confidence interval; ACEI, Angiotensin-converting-enzyme 
inhibitors; ARB, Angiotensin II receptor blockers; OAD, Oral antidiabetic drugs.
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patients with diabetes mellitus.9 Moreover, in the case of hypertension, 
studies had also reported that the improvement of CEC and EPC levels 
was observed after GMLE administration in hypertensive patients.27 
Furthermore, in the case of dyslipidemia, alteration of EPC and CEC 
levels was also found in dyslipidemia patients after GMLE administra-
tion.15 Those evidences suggested that GMLE might play a crucial role 
in the development of endothelial dysfunction and its associated diseas-
es. However, further investigations are needed to determine the precise 
role of GMLE in each endothelial dysfunction associated disease.
To the best of our knowledge, our findings were the first study evaluat-
ing the effect of GMLE to the levels of CEC and EPC in patients with 
high framingham score. Our current study might provide the initial data 
in evaluating the effect of GMLE on endothelial dysfuntion, assessed by 
the levels of CEC and EPC in patients with high framingham score. We 
expected that up-coming studies might be existed to investigate further 
regarding the effect of GMLE on endothelial dysfunction by using the 
findings of our study as the basic data.
In our current study, we had several limitations. First, several factors 
that might affect the severity of endothelial dysfuntion including 
tobacco use, family history of premature coronary events, and activity 
status were not controlled for.30 Second, our findings should be 
interpreted with caution due to relatively small sample size. Third, in 
our study, the measure outcomes were only limited to the levels of CEC 
and EPC. Further studies evaluating clinical outcomes after GMLE 
administration might be required. Fourth, data retrieved in our current 
study were obtained from single center. Further studies involving 
multiple centers might be needed to achieve findings with better 
evidence.  
5. Conclusion
 Administration of GMLE as adjuvant therapy is associated 
with the improvement of CEC and EPC levels in patients with high 
framingham scores. In addition, GMLE administration is also associated 
with the improvement of CEC and EPC levels in combination with  
optimal routine treatment including statin, ACEI or ARB, and oral 
antidiabetic drugs for the underlying disease.
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